VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHS AL 2020 | Treatment of NPM1-mutated AML: intensive standard treatment

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the value of intensive chemotherapy compared with novel targeted treatments for NPM1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter